The transition will be made immediately, the Irvine, Calif.-based company said.
“I would like to thank Harold for the leadership and commitment he has demonstrated over the last three years. We are grateful for his contributions to product quality and for his steadfast dedication to Biolase. We thank him for his continued support and wish him all the best in this new phase of his professional career. We are pleased to have John take on this interim role. Since joining Biolase, he has become an integral part of the team and has demonstrated his leadership skills by improving our cash position and securing a firm financial footing for Biolase,” board chair Dr. Jonathan Lord said in a prepared statement.
Biolase also said that it asked Dr. Lord to lead its exploration of strategic alternatives including licensing, joint ventures, partnerships, mergers or other options, according to an SEC filing. The company said it will not comment further on the process until it believes “disclosure is appropriate.”
“Biolase has been and continues to be the leader in all-tissue lasers in the U.S. and outside the U.S. – our award winning Waterlase platform has set the bar high in the dental field. The utility of lasers in dentistry continues to expand as evidenced by success in treating implant periodontitis with our proprietary Side Firing Tip. On behalf of the Board, I would like to take the opportunity to thank all of our stakeholders – our customers, employees and shareholders for all of the loyalty they have shown through the years and for their belief in our goal to change the face of dentistry,” Dr. Lord said in an SEC filing.
Endotronix said this week it appointed John Flavin as its new chief financial officer as the company looks to scale its business operations in preparation of clinical trials and commercialization of its Cordella Heart Failure system.
Prior to joining Endotronix, Flavin served as head of the Polsky Center for Entrepreneurship and Innovation at the University of Chicago and founded the Polsky Exchange start-up incubator. Flavin has also held prez & CFO positions at Advanced Life Sciences and MediChem Life Sciences.
“John has a rich background in life science technology commercialization, both from doing it directly in a hands-on operating role as well as creating an environment in which it can flourish. His expertise will be a great asset as we prepare to commercialize the Cordella System later this year,” CEO & co-founder Harry Rowland said in a press release.
“I’ve spent much of my time at the University of Chicago fostering innovations that combine data science and healthcare because I truly believe the combination will have the most direct impact on improving outcomes for complex health conditions. The Endotronix solution is an excellent example of this and I’m thrilled to be joining the team as they enter a new phase,” Flavin said in a prepared statement.
Mock replaces current senior VP and CFO Andy Wilson, who is retiring from the company. Wilson will stay on as an advisor to the company during the transitional period, the Waltham, Mass.-based company said.
“I am excited to welcome Jamey to PerkinElmer and look forward to his contributions, as he brings extensive experience overseeing the financial and commercial management of leading global organizations. Jamey’s financial leadership capabilities are an ideal complement to our focus on driving PerkinElmer to its next phase of growth and profitability,” prez & CEO Robert Friel said in a prepared statement.
Conventus Orthopaedics said this week it named former cardiovascular imaging start-up Infraredx CFO Jonathan Isenburg as its new chief financial officer.
During his time with Infraredx, Isenburg reportedly led the group through a dual-track IPO and a merger & acquisition process which ended in its sale to Nipro. Prior to joining Infraredx, Isenburg served as financial advisory services manager at RSM, Conventus said.
“I am pleased to welcome Jonathan to the Conventus team. We will benefit from his expertise and leadership as we continue to grow commercial operations and accelerate development to bring the CAGE platform technology to additional types of fractures. Jonathan is an experienced medical device industry executive who has excelled in corporate finance, strategy, business development and operations. He has a proven track record of success and we look forward to utilizing his many talents,” CEO Matthew Jewett said in a press release.
“It is with much enthusiasm that I join the outstanding Conventus team who has developed true game-changing technology for the treatment of simple and complex fractures throughout the anatomy. I look forward to working with them to grow the business and bring this innovative and less invasive surgical solution to more patients,” Isenburg said in a prepared statement.
Healthcare venture capitalist Sami Hamade has passed away due to liver failure from recently diagnosed cancer, according to a report from Axios.
Hamade spent the past three years with Apple Tree Partners, and held board seats with VytronUS, Tusker Medical, Rox Medical and Gala Therapeutics.
He previously served as a partner of Aberdare Ventures and helped invest in Ablation Frontiers, which was acquired by Medtronic. Before his position at Aberdare, he led venture capital for Guidant and worked in an operational role within ACS’ interventional cardiology unit, according to the Axios report.
- Frequency Therapeutics taps Chin as chief medical officer
- Omnicell appoints Seidelmann as chief commercial officer
- Henry Schein names Pendergast as IT lead
- NSF Health Sciences Certification taps Serpa for med device certification role
- McKeon Products appoints Springhetti as marketing VP
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.